Related News

2.3 million job openings by 2027 in India’s AI sector: Bain & Company

2.3 mn job openings by 2027 in India’s AI sector, offers opportunity to reskill over 1 mn workers: Bain & Company NEW DELHI: Contrary to the common perception that Artificial

What Is BLM Plaza: Workers begin dismantling Black Lives Matter Plaza in Washington; Republicans cheer ‘America is healing’

Workers began dismantling Black Lives Matter Plaza in Washington. The process of dismantling the Black Lives Matter plaza in Washington began Monday marking the end of an era for a

WPL 2025: Harmanpreet Kaur stars as Mumbai Indians beat Gujarat Giants by nine runs

Mumbai Indians’ Harmanpreet Kaur plays a shot (PTI Photo) NEW DELHI: Harmanpreet Kaur’s fluent half-century, coupled with an exceptional bowling performance, propelled Mumbai Indians to a nine-run victory over Gujarat

A Young Prince of Luxembourg Dies of a Rare Genetic Disease

A prince of Luxembourg has died at 22 of a genetic disease for which he spent his brief life raising awareness. Prince Frederik, the second cousin of the heir to

China’s retaliatory tariffs are a direct hit to U.S. farmers

China’s retaliatory tariffs went into effect Monday, spelling trouble for American farmers by making U.S.-grown crops more expensive for their top purchaser. Beijing imposed the levies in response to President

15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark

Word Count: 337 | Estimated Reading Time: 2 minutes

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to treat attention deficit hyperactivity disorder in the U.S. market. Approximately 14.76 lakh bottles of Atomoxetine Capsules in various strengths are being recalled by Glenmark Pharmaceuticals Inc., USA.

Glenmark Pharmaceuticals is a global pharmaceutical company based in India. Founded in 1977, the company has strong presence in dermatology, respiratory, etc and has operations spanning across multiple countries, including the U.S. and Europe.

The U.S. Food and Drug Administration (USFDA) stated in its most recent Enforcement Report that the corporation is recalling the impacted lot because of “CGMP Deviations.” The “presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit” is the reason for the recall, it continued.

According to the USFDA, the manufactured-in-India medicine in strengths ranging from 10 mg to 100 mg is being recalled by Glenmark Pharmaceuticals Inc., situated in New Jersey, USA.

According to the USFDA, a Class II recall is started when there is a remote chance of substantial adverse health effects or when using or being exposed to a product that violates the law may result in short-term or medically reversible negative health effects.

The neuro-developmental disease known as ADHD impairs a person’s capacity for concentration, impulse control, and activity regulation. ADHD is among the most prevalent mental illnesses that impact kids. In youngsters, attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent mental illnesses. Impulsivity, hyperactivity, and inattention are signs of ADHD.

ADHD is seen as a chronic and incapacitating disorder that affects a person’s everyday functioning, interpersonal connections, academic and professional accomplishments, and many other areas of their life. Relationship instability, subpar performance at work or school, low self-esteem, and other issues can result from adult ADHD.

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Source link